 Phosphodiesterase III inhibition adrenoreceptor stimulation milrinone alternative treatment severe heart failure High levels endogenous plasma catecholamines patients severe congestive heart failure down-regulation myocardial beta-adrenoreceptors adrenoreceptor agonists dobutamine effective treatment patients Phosphodiesterase III inhibitors independent adrenoreceptor activity plasma catecholamine levels agents likely effective treatment severe heart failure present study initial late hemodynamic effects dobutamine milrinone infusions patients severe heart failure New York Heart Association class III New York Heart Association class IV Dobutamine prescribed maximum dose micrograms/kg/min hours patients patients dose dobutamine infusion drug-related increase heart rate beats/min patients hemodynamic improvement hours maximum dose micrograms/kg/min Dobutamine administration patients account unfavorable hemodynamic condition therapy intravenous milrinone patients side effects comparison hemodynamic effects infusion possible patients patients observation periods increase heart rate beats/min hour equal dobutamine increase milrinone Stroke volume dobutamine infusion hour hours milrinone therapy volume equal level end infusion Pulmonary capillary wedge pressure PCWP equal milrinone therapy mm Hg minutes mm Hg hours dobutamine infusion PCWP delayed decrease mm Hg hours mm Hg hours ABSTRACT TRUNCATED AT WORDS